InvestorsHub Logo
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

Re: None

Monday, 06/03/2019 8:10:41 AM

Monday, June 03, 2019 8:10:41 AM

Post# of 6035
News: $HTBX Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

Clinicalbenefit observed in 55% of patients receiving HS-110 plus nivolumab aftercheckpoint inhibitor treatment failure HS-110 incombination with nivolumab demonstrates clinical activity in low CD8+ TIL "coldtumor" patients and PD-L1 negative tumors Theoccurrence of dermal injection sit...

Got this from https://marketwirenews.com/news-releases/heat-biologics-announces-promising-interim-phase-2-lung-cancer-data-suggesting-that-hs-110-plus-nivolumab-may-restore-clinical-benefit-after-checkpoint-inhibitor-treatment-failure-8287598.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NHWK News